

## Ociperlimab

<b>Cat. No.:</b>	HY-P99763
<b>CAS No.:</b>	2342597-93-5
<b>Target:</b>	Others
<b>Pathway:</b>	Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity ( $K_D = 0.135$ nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer <sup>[1][2]</sup> .	
<b>In Vitro</b>	Ociperlimab (BGB-A1217; 0-10 $\mu$ g/mL) enhances IFN- $\gamma$ secretion by cytomegalovirus-specific T cells <sup>[1]</sup> . Ociperlimab (1-1000 ng/mL) activates NK and monocytes in an Fc-dependent manner <sup>[1]</sup> . Ociperlimab removes TIGIT from T cell surface through Fc-dependent endocytosis in vitro <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
<b>In Vivo</b>	Ociperlimab (BGB-A1217; 3 and 10 mg/kg; i.p.; CT26 WT tumor-bearing humanized TIGIT knock-in mice and MC38 tumor-bearing humanized TIGIT knock-in mice) elicits anti-tumor efficacy in an Fc-dependent manner <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	<b>Animal Model:</b>	CT26 WT tumor-bearing humanized TIGIT knock-in mice and MC38 tumor-bearing humanized TIGIT knock-in mice <sup>[1]</sup>
	<b>Dosage:</b>	3 and 10 mg/kg
	<b>Administration:</b>	Intraperitoneal injection
	<b>Result:</b>	Inhibited tumor growth compared to the single agent treatment groups.

### REFERENCES

[1]. Chen X, et, al. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models. *Front Immunol.* 2022 Feb 22;13:828319.

[2]. Zhu J, et, al. Immune Checkpoints and targeted agents in relapse and graft-versus-host disease after hematopoietic stem cell transplantation. *Mol Biol Rep.* 2022 Dec 26.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA